

US\$1.8m AnteoBind Purchase Agreement over 5 years

Serum Institute of India – World's largest vaccine manufacturer

BRISBANE, AUSTRALIA, 30 July 2024: AnteoTech Ltd (ASX: ADO) (AnteoTech or the Company) a revenue stage company, providing solutions for the clean energy and life sciences markets using proprietary technologies, is pleased to announce the Company has entered a five year Purchase Agreement for an AnteoBindTM product (Product) with US\$370,000 annual minimum orders (the Agreement), with the world's largest vaccine producer, Serum Institute of India Private Limited. (Serum Institute of India).

Key Points

- 5-year term of Agreement with US\$370,000 minimum annual take or pay orders
- Product for use in vaccine development by Serum Institute of India
- Supply Agreement contains pricing to support the anticipated future increase in demand
- AnteoTech has existing capacity to meet the customer requirements
- Serum Institute of India produces over 1.5B vaccine doses and US\$3B revenues annually
- First US\$185,000 order for the Product received with shipment and payment in August

David Radford, Managing Director & Chief Executive Officer of AnteoTech commented:

"We are excited to extend our close working relationship with Serum Institute of India, one of the leaders and innovators in the global vaccine market, with our unique AnteoBindTM product becoming an integral part of their vaccine development and production process. The scale and leading-edge technology of the Serum Institute of India's operations in Pune, India, underpin their commitment to quality and we look forward to supporting them.


Most importantly, this new Agreement sets out a framework for both parties to build the relationship, with orders expected to exceed the US\$370,000 minimum orders per annum as we work together towards increasing our partnership and product usage. I am proud of our team which has delivered this first major commercial agreement as we build out our business in life sciences and clean energy, to deliver revenues and value."

Strategic rationale for Agreement

As a global leader in the development and manufacture of vaccines, Serum Institute of India has been working collaboratively with the AnteoTech life sciences team to adopt the Product which has demonstrated material advantages as a timely, accurate and cost-effective solution when compared to other currently available methods of quality testing and control.

Both AnteoTech and Serum Institute of India have structured this supply agreement to maintain ongoing and minimum supply levels of the Product, over the life of the Serum Institute of India's new vaccine products, which are typically 20 years following regulatory approval. As a partnering style arrangement, the Agreement also allows the parties to increase orders for the use of the Product once regulatory approvals are obtained for development of current vaccines as well as when other new vaccines are developed by Serum Institute of India, in the future.









Summary of Commercial Terms

AnteoTech and Serum Institute of India have executed the Agreement to establish the framework for ongoing orders of the Product. The Agreement remains commercial in confidence with the key terms summarised below:

- Customary terms relating to ongoing production, shipping and supply of the Product for use in the production process by Serum Institute of India;
- Term of five years from the execution date, subject to the terms of the Agreement;
- Commitment to purchase a minimum quantity of the Product for US\$370,000 each year for the next five years, on a take or pay basis;
- Renewal of contract on mutually acceptable terms for follow on periods;
- Shipments of the kits will be made twice a year;
- Pricing framework for orders of the Product over and above minimum order levels;
- Customary requirements on maintaining licences, manufacturing standards, access by regulatory agencies, testing and shipping protocols;
- No exclusivity or restrictions on AnteoTech supplying the Product to other customers; and
- No grant by either party over current or future generated intellectual property.

The Product for use by Serum Institute of India is specifically designed for their needs but requires no additional formulation by AnteoTech. There is current capacity at the Company's Brisbane facilities to meet the minimum order requirements, as well as any potential medium-term increase in demand, with no additional capex expenditure required.

About Serum Institute of India

Serum Institute of India Pvt. Ltd. is now the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses) which includes Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella as well as Pneumococcal and Covid-19 vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute of India. These vaccines are accredited by the World Health Organisation and are being used in around 170 countries in national immunization programs, saving millions of lives throughout the world.

This announcement has been authorised for release by the Management of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech - (ASX:ADO)









AnteoTech is a revenue-stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo XTM, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry. The portfolio includes a proprietary high silicon anode, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets; from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (Estimates and Projections). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.



